Is there an emerging threat of drug-resistant fungal infections? The jock itch case study

Combat drug-resistant fungal infections like Trichophyton indotineae in India through prudent medication use, public education, and good hygiene practices.

The rise of drug-resistant fungal infections, notably Trichophyton indotineae, is emerging as a significant health concern in India. This resilient dermatophyte, linked to the misuse of topical steroids, poses challenges for both patients and healthcare providers. 

Imagine battling a skin infection that refuses to heal despite multiple treatments. This is the reality for many who face infections caused by Trichophyton indotineae, commonly known as ringworm or jock itch. First identified in India, this fungus has now spread to several countries worldwide. The inappropriate use of steroid creams has exacerbated the problem, making this strain particularly hard to treat. 

Shyam Verma, one of the world’s leading experts in dermatophytosis and based at Nirvan Skin Clinic, Vadodara, Gujarat, emphasises the need for careful classification: “It’s premature to label it Trichophyton indotineae based on a few cases. This dermatophyte, found in various regions including Australia and Oman, belongs to genotype VIII within the T. mentagrophytes/T. interdigitale species complex,” he says. 

Patients often present with persistent, treatment-resistant rashes that can easily be mistaken for eczema or other skin conditions, delaying effective treatment. These rashes can be red, scaly, and itchy, making them similar to more common dermatological issues. The misdiagnosis of these infections often leads to the use of ineffective treatments, which not only prolongs patient suffering but also allows the infection to worsen. 

The diagnostic process involves not just clinical examination but also laboratory tests, such as fungal cultures and molecular diagnostics, to confirm the presence of resistant fungal strains. Educating patients about the importance of following through with recommended tests and treatments is vital. Misdiagnosis and delayed treatment can lead to the spread of the infection, not only worsening the individual’s condition but also increasing the risk of transmission within the community. 

Ravi (name changed), a patient managing Trichophyton indotineae, shares, “I experienced persistent rashes for months, and was misdiagnosed initially as eczema. Once correctly identified, the appropriate treatment made a significant difference. However, the infection spread among my family members, and the relentless itching was unbearable.” His experience underscores the importance of accurate diagnosis and specialised care in managing these infections effectively. By improving diagnostic accuracy and educating both healthcare providers and patients, we can better manage and treat these challenging infections, ultimately reducing their impact on public health. 

Trichophyton indotineae is a newly-identified dermatophyte species that has been found in  near-epidemic form on the Indian subcontinent. This fungus, identical to genotype VIII within the T. mentagrophytes/T. interdigitale species complex, was described in 2019 by sequencing the Internal Transcribed Spacer (ITS) region of ribosomal DNA. More than 10 ITS genotypes of T. interdigitale and T. mentagrophytes can now be identified. T. indotineae causes inflammatory and itchy, often widespread dermatophytosis affecting the groins, gluteal region, trunk, and face, affecting patients of all ages and genders.